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Abstract
Background: Therapeutic strategies exist for human pulmonary neoplasia, however due to the
heterogeneity of the disease, most are not very effective. The innate immunity gene, toll-like
receptor 4 (TLR4), protects against chronic pulmonary inflammation and tumorigenesis in mice, but
the mechanism is unclear. This study was designed to identify TLR4-mediated gene expression
pathways that may be used as prognostic indicators of susceptibility to lung tumorigenesis in mice
and provide insight into the mechanism.
Methods: Whole lung mRNA was isolated from C.C3H-Tlr4Lps-d (BALBLps-d; Tlr4 mutant) and
BALB/c (Tlr4 normal) mice following butylated hydroxytoluene (BHT)-treatment (four weekly ip.
injections; 150-200 mg/kg/each; "promotion"). mRNA from micro-dissected tumors (adenomas)
and adjacent uninvolved tissue from both strains were also compared 27 wks after a single
carcinogen injection (3-methylcholanthrene (MCA), 10 μg/g; "control") or followed by BHT (6
weekly ip. injections; 125-200 mg/kg/each; "progression"). Bronchoalveolar lavage fluid was
analyzed for inflammatory cell content and total protein determination, a marker of lung
hyperpermeability; inflammation was also assessed using immunohistochemical staining for
macrophages (F4/80) and lymphocytes (CD3) in mice bearing tumors (progression).
Results: During promotion, the majority of genes identified in the BALBLps-d compared to BALB/c
mice (P < 0.05) were involved in epithelial growth factor receptor (EGFR) signaling (e.g. epiregulin
(Ereg)), secreted phosphoprotein 1(Spp1)), which can lead to cell growth and eventual tumor
development. Inflammation was significantly higher in BALBLps-d compared to BALB/c mice during
progression, similar to the observed response during tumor promotion in these strains. Increases
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in genes involved in signaling through the EGFR pathway (e.g. Ereg, Spp1) were also observed during
progression in addition to continued inflammation, chemotactic, and immune response gene
expression in the BALBLps-d versus BALB/c mice (P  < 0.05), which appears to provide more
favorable conditions for cell growth and tumor development. In support of these findings, the
BALB/c mice also had significantly reduced expression of many immune response and inflammatory
genes in both the tumors and uninvolved tissue.
Conclusion:  This transcriptomic study determined the protective effect of TLR4 in lung
carcinogenesis inhibition of multiple pathways including EGFR (e.g. Ereg), inflammatory response
genes (e.g. Cxcl5), chemotaxis (e.g. Ccr1) and other cell proliferation genes (e.g. Arg1, Pthlh). Future
studies will determine the utility of these pathways as indicators of immune system deficiencies and
tumorigenesis.
Introduction
Adenocarcinoma (AC), a non-small cell lung carcinoma
(NSCLC) [1], remains the leading type of lung cancer
among smokers and nonsmokers. AC is often not detected
until advanced stages of the disease thus making it the
most clinically-intractable of lung cancers [1]. Therefore,
it is critical to discover biomarkers of early stages of AC
that would allow early detection and to find new sites at
which chemopreventive agents could act to inhibit further
neoplastic progression. Chronic inflammatory lung dis-
eases, such as COPD and asthma, predispose to lung neo-
plasia [2-5]. Thus, inflammatory mediators and effector
pathways might provide a source of early biomarkers and
further insight into mechanisms of lung cancer.
Spontaneous or chemically-induced mouse lung neo-
plasms resemble those of human AC in anatomy, his-
togenesis, and molecular features [6], thereby facilitating
mouse to human comparisons. Multiple exposures to
butylated hydroxytoluene (BHT) elicit lung injury and
inflammation during tumor promotion that are signifi-
cantly correlated with tumor multiplicity in mice [7,8].
This 2-stage carcinogenesis model uses a low dose of a
tobacco smokexs carcinogen, 3-methlycholanthrene
(MCA), followed by multiple doses of BHT as the tumor
promoter [9]. It is not BHT per se, but oxidative metabo-
lites of BHT produced in high concentrations in mouse
lung that are responsible for these pneumotoxicities and
inflammatory activities [10]. Understanding the molecu-
lar events that occur early in the tumorigenic process (i.e.
promotion including chronic inflammation and prolifer-
ation) may be critical to understanding the later events
that occur during progression.
Tlr4 is an innate immunity gene involved in exacerbation
of responses to several pulmonary agonists including
endotoxin (lipopolysaccarride, LPS [11]) and ozone (O3
[12]), and injury protection from pulmonary insults,
including hyperoxia [13] and allergic inflammation [14].
Several epidemiological studies found significant
decreases in lung cancer risk in individuals such as farm
and textile workers that were exposed to endotoxin [15-
17]. Because TLR4 is the primary receptor that binds endo-
toxin [11], it is likely that TLR4 is involved in protection
observed with endotoxin exposure. TLR4 also confers pro-
tection against human gastric and mouse cutaneous carci-
nomas [18,19]. The mechanism behind TLR4-mediated
protection is unclear.
We previously demonstrated that TLR4 protects against
BHT-induced chronic pulmonary inflammation and
tumor promotion [20]. C.C3H-Tlr4Lps-d (BALBLps-d) mice
have a missense mutation in Tlr4 [21] that renders TLR4
dysfunctional. Bronchoalveolar lavage fluid (BALF)
inflammatory markers were significantly elevated in BAL-
BLps-d mice compared to BALB/c (BALB; Tlr4 wild type)
mice following BHT treatment [20]. Significantly
increased tumor multiplicity (60%) was also found in
BALBLps-d compared to BALB mice in response to MCA/
BHT induced tumor promotion. However, the down-
stream mechanism regulating this protective response
remains unknown.
In the present investigation, we hypothesized that gene
transcripts that are highly correlated to TLR4 associate
with differential susceptibility to an early stage (BHT-
treatment) and a later stage (progression) of lung tumori-
genesis. To test this hypothesis we used two methods to
analyze transcriptome responses in lung tissue from BALB
and BALBLps-d mice during promotion, and in tumors and
uninvolved lung tissue in advanced stages of tumorigene-
sis. The first statistical method (supervised) assigned a sig-
nificance value to transcript changes. The second method
(unsupervised, pattern analysis) used k-means clustering
to identify additional patterns which may have remained
hidden. These methods identified changes in transcripts
known to be downstream of TLR4 and others not previ-
ously linked to this gene. We suggest that these pathways
and interactions amongst the genes identified during
tumor promotion influence the TLR4-mediated response
observed during progression of tumorigenesis.Molecular Cancer 2009, 8:107 http://www.molecular-cancer.com/content/8/1/107
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Methods
Animals
Male 5-7 wk. old BALB/c (BALB; Tlr4 wild type) and C.C3-
Tlr4Lps-d/J (BALBLps-d; Tlr4 dominant negative) mice were
purchased from Jackson Laboratories (Bar Harbor, ME).
Mice acclimated for 1 wk prior to treatment. All animal
use was conducted in facilities accredited by the Associa-
tion for the Assessment and Accreditation of Laboratory
Animal Care and approved by the NIEHS Animal Care
and Use Committee and the MSU Institutional Animal
Care and Use Committee. Mice were housed in shoebox
cages in a humidity and temperature-controlled room and
provided water and pelleted open-formula rodent diet
NIH-07 (Zeigler Brothers, Gardners, PA.) ad libitum.
Experimental design
The two protocols used for these studies (see Additional
file 1, Figure S1) were based on previous studies demon-
strating a correlation between chronic inflammation and
tumor promotion [7]. To induce inflammation (Protocol
1: promotion; Additional file 1, Figure S1: A), mice were
injected intraperitoneally (ip.) with BHT (Sigma, St.
Louis, MO) weekly for 4 weeks (150 mg/kg for the first
dose followed by 200 mg/kg for the next 3 doses). Mice
were then sacrificed 1 or 3 days following the last BHT
dose. For BHT-induced tumor studies (Protocol 2: pro-
gression stage; Additional file 1: Figure S1: B), 10 μg MCA/
gm (Sigma) body wt. was injected ip., followed by 150 mg
BHT/kg or corn oil vehicle control one week later. Five
additional weekly 200 mg/kg BHT doses or vehicle con-
trol doses were administered to maximize tumor promo-
tion [22]. Mice were sacrificed 27 wks after MCA injection.
Because fewer than 0.5 tumors/mouse result from MCA
alone, the tumors that develop after MCA/BHT treatment
are primarily those promoted by MCA.
The left lung of each mouse was clamped off at the main-
stem bronchus and the right lung was lavaged for inflam-
matory infiltrate analysis [12,20]. Briefly, four aliquots of
HBSS (Sigma) were inserted sequentially into the lung
based on body weight (17.5 ml/kg). The first lavage was
used for protein analysis (BioRad protein assay, BioRad,
Hercules, CA) as a measure of lung hyperpermeability.
Total pooled cells from the four lavages were then
counted, followed by cytocentrifugation (Shandon South-
ern Products, Pittsburgh, PA). The slides were then stained
with a modified Wright's stain (Hema 3 Stain Set, Fisher
Scientific, Pittsburgh, PA) to differentiate inflammatory
cells by morphology, including PMNs, alveolar macro-
phages, lymphocytes, and epithelial cells. The left lung
was snap frozen in liquid nitrogen. For MCA/BHT treated
mice (Protocol 2), the lavaged right lung was inflation-
fixed with 10% formalin, processed, and embedded.
Tumors (adenomas) were carefully micro-dissected away
from the adjacent tissue on left lung lobe using a Leica
S6D stereo microscope (Leica Microsystems, Inc., Ban-
nockburn, IL) and then snap frozen, similar to other stud-
ies [23-25]. Remaining whole lung tissue was used as the
uninvolved tissue. In addition, whole lung tissue was also
used for the MCA/oil treatment group. Due to the manner
in which the tumors were micro-dissected away from the
normal adjacent uninvolved tissue, there is a possibility
that the uninvolved tissue may contain some remaining
smaller lesions as well as tumor cells from the periphery.
Immunohistochemistry for CD3 and F4/80
5 μm thick sections were stained using antibodies for CD3
(ab5690; Abcam, Cambridge, MA) as a pan-T-lymphocyte
marker and F4/80 (MF48000; Caltag, Burlingame, CA) as
a macrophage marker, following standard protocols at:
http://www.niehs.nih.gov/research/atniehs/labs/lep/
path-support/immuno/.
Total lung RNA isolation and cDNA synthesis for mRNA 
analyses
Total RNA was isolated from the left lung lobe using RNe-
asy Mini Kits (Qiagen, Valencia, CA) following kit specifi-
cations, including DNase 1 treatment. cDNA was
synthesized as described previously [26]. For Protocol 1,
RNA was isolated from each of three replicate mice for
each experimental group (experimental groups = oil con-
trol, 1-day, and 3-days after BHT, three replicated per
group). For Protocol 2, tumors from 2 to 3 mice were
pooled to obtain sufficient material; uninvolved tissue
from the same mice was also pooled for control. There
were two replicates for each experimental group (MCA/
oil, MCA/BHT tumor tissue and MCA/BHT uninvolved
tissue) except for the BALB tumor group where the inci-
dence of tumors was low.
Affymetrix Mouse 430A_MOE array analysis
Total RNA was used only after it passed quality testing per-
formed using a 2100 Bioanalyzer (Agilent Technologies,
Inc., Santa Clara, CA). Gene expression analysis was con-
ducted using Affymetrix MOE430A or MOE430Av2 Gene-
Chip®  arrays (Affymetrix, Santa Clara, CA) as
recommended by the manufacturer. Total RNA (1 μg) was
amplified using the Affymetrix One-Cycle cDNA Synthesis
protocol. For each array, 15 μg of amplified biotin-cRNAs
was fragmented and hybridized to the array for 16 hours
at 45°C in a rotating hybridization oven using the
Affymetrix Eukaryotic Target Hybridization Controls and
protocol. Slides were stained with steptavidin/phyco-
erythrin using a double-antibody staining procedure and
washed utilizing the Mini_euk2v3 Protocol of the Affyme-
trix Fluidics Station FS450 for antibody amplification.
Arrays were scanned with an Affymetrix Scanner 3000 and
data obtained using the GeneChip® Operating Software.Molecular Cancer 2009, 8:107 http://www.molecular-cancer.com/content/8/1/107
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The CEL files for each array type were normalized and
genes with altered expression level were selected using k-
means clustering and ANOVA (p < 0.05). The raw data
discussed in this publication have been deposited into
NCBI Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/, Series GSE8504) and NIEHS
Chemical Effects in Biological Systems (CEBS, http://
cebs.niehs.nih.gov/, accession 005-00003-0030-000-1).
Starting and ending gene lists are found in Additional file
2, Table S1. The details of the process to identify genes
with altered transcript levels using the supervised and
unsupervised methods are found in Additional file 3.
Quantitative real time PCR (qRTPCR)
qRTPCR was performed using Sybr green assays on an
Applied Biosystems 7900 Prism Sequence Detection Sys-
tem as follows: 12.5 μl Power Sybr Green PCR master mix
(Applied Biosystems, Foster City, CA), 200 nM forward
and reverse primers, 5.5 μl nuclease-free dH2O, and 2 μl
of cDNA per 25 μl reaction. The reverse and forward prim-
ers can be found in Additional file 4, Table S2. PCR reac-
tion conditions and data analysis were performed
according to the manufacturer's protocol (User bulletin
no.2, Applied Biosystems Prism 7700 Sequence Detection
System). 18S was used to normalize all genes of interest
since it did not vary across genotypes or treatments. Some
transcript changes identified by microarray analysis were
confirmed using qRTPCR in the same samples (Protocol
1) and in the same samples plus samples from a parallel
study (Protocol 2).
Statistics for BALF analysis and qRTPCR
Data are expressed as the group mean ± SEM. Two-way
ANOVA was used to evaluate the effects of strain (BALB vs.
BALBLps-d) and treatment (MCA/oil and MCA/BHT) on
BAL phenotypes. A 3-way ANOVA was performed for
treatment, time (0, 1, or 3 days), and strain effects on
mRNA expression data under Protocol 1 (promotion). A
2-way ANOVA was performed for the treatment (MCA/
oil, MCA/BHT tumor tissue, and MCA/BHT uninvolved
tissue) and strain effects on mRNA expression data under
Protocol 2 (progression). Student-Newman-Keuls test was
used for a posteriori comparisons of means. All analyses
were performed using a commercial statistical analysis
package (SigmaStat; Jandel Scientific Software, San Rafael,
CA). Statistical significance was accepted at P < 0.05.
Results
BHT-induced transcriptome changes between BALB vs. 
BALBLps-d mice during tumor promotion (Protocol 1, 
"Promotion")
Three different gene expression profiles were identified
(genes for each are in Additional file 2, Table S1, Tab A).
Figure 1 and Additional file 5, Figure S2 illustrate one of
the profiles found by supervised (Fig 1A) and unsuper-
vised (Fig 1B) methods. The profiles are biologically sim-
ilar, i.e. expression increased by one standard deviation
(BALB) or more (BALBLps-d) in mice sampled one day fol-
lowing the last BHT injection compared to mice three days
after BHT, or mice receiving oil vehicle control. We termed
this profile "BHT_1day_up". Some genes with this profile
were identified by both methods, and others found by
only one method. We also found two BHT_1day_down
profiles by supervised and unsupervised methods (see
Additional file 2, Table S1, Tab A).
Transcripts with the BHT_1day_up profile have Gene
Ontology (GO) functions involving cell cycle and growth,
transcription, cell shape and morphogenesis, protein syn-
Gene expression that increased in the BALBLps-d mice com- pared to BALB mice following chronic BHT Figure 1
Gene expression that increased in the BALBLps-d mice 
compared to BALB mice following chronic BHT. Two 
methods of analysis, supervised and unsupervised, were used 
to determine the genes increased at 1 day following BHT. A. 
Cluster 3 identified using statistical (GeneSpring) analysis in 
chronic BHT-treated BALB and BALBLps-d mice over a time 
course (oil and 1 and 3 day following chronic BHT). Each ver-
tical line represents one sample for each strain for an n = 3 
(oil, BHT 1 day, BHT 3 day), indicated by the small horizontal 
black line above each treatment on the x-axis. B. Profile anal-
ysis (Spotfire) similar to that of cluster 3. Each vertical line 
represents one sample for each strain for an n = 3 (oil, BHT 
1 day, BHT 3 day). Z-score (y-axis) is the intensity in terms 
of standard deviations (SD) from the mean. The z-score was 
calculated by subtracting the mean and dividing by the SD for 
each probeset. See Additional file 5, Figure S2 for supervised 
and unsupervised analyses depicted as a heat map.
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Table 1: Representative gene expression changes increased in BALBLsp-d compared to BALB mice.
Gene Symbol Gene Name Affymetrix Probe ID Major GO Category(ies)
Angiogenesis
Hbegf† heparin-binding EGF-like growth factor 1418349_at angiogenesis; blastocyst growth
Mmp19† matrix metallopeptidase 19 1421977_at angiogenesis; peptidoglycan metabolic process
Timp1† tissue inhibitor of metallo-proteinase 1 1460227_at erythrocyte maturation
Cell cycle and cell growth
Cdkn1a† cyclin-dependent kinase inhibitor 1A (P21) 1424638_at regulation of progression through cell cycle; response to 
DNA damage stimulus
Ereg†‡ epiregulin 1419431_at regulation of progression through cell cycle; angiogenesis
Mina myc induced nuclear antigen 1451042_a_at regulation of cell proliferation
Myc† myelocytomatosis oncogene 1424942_a_at regulation of progression through cell cycle; release of 
cytochrome c from mitochondria
Socs3 suppressor of cytokine signaling 3 1455899_x_at regulation of cell growth; regulation of protein amino 
acid phosphorylation
Cell shape and morphogenesis
Krt19 keratin 19 1417156_at cytoskeleton organization and biogenesis
Tnc† tenascin C 1416342_at cell adhesion
Tuba1c tubulin, alpha 1C 1416128_at microtubule-based process and movement
Inflammatory and immune response
Il6† interleukin 6 1450297_at neutrophil apoptosis
Lif† leukemia inhibitory factor 1421207_at immune response; tyrosine phosphorylation of stat3 
protein
Spp1† secreted phosphoprotein 1 1449254_at ossification; anti-apoptosis
Protein synthesis and turnover
Eif1a eukaryotic translation initiation factor 1A 1419736_a_at translation and initiation
Hras1† Harvey rat sarcoma virus oncogene 1 1422407_s_at translation; endocytosis
Nola1 nucleolar protein family A, member 1 1418305_s_at rRNA processing; ribosome biogenesis and assembly
Nola2 nucleolar protein family A, member 2 1416605_at rRNA processing; translation
Nol5A nucleolar protein 5 1450986_at ribosome biogenesis and assembly
Nmd3 NMD3 homolog 1437238_x_at ribosomal large subunit export from nucleus
Rps6ka3 ribosomal protein S6 kinase polypeptide 3 1427299_at protein amino acid phosphorylation; ribosome biogenesis 
and assembly
Protein targeting
Afp† alpha fetoprotein 1416646_at ovulation; transport
Bcl3† B-cell leukemia/lymphoma 3 1418133_at protein import into nucleus, translocation; follicular 
dendritic cell differentiation
Bnip1 BCL2/adenovirus E1B interacting protein 1, 
NIP1
1427908_at ER to Golgi vesicle-mediated transport; apoptosis
Nup62 Nucleoporin 62 1438917_x_at protein targeting; transport
Transcription, processing, and chromatin structure
Bhlhb8 basic helix-loop-helix domain containing, 
class B, 8
1449233_at regulation of transcription, DNA-dependent
Ddx39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
39
1423643_at mRNA processing; RNA splicing
Hmga1† high mobility group AT-hook 1 1416184_s_at DNA packaging; transcription
Lmna lamin A 1425472_a_at nuclear membrane organization and biogenesis
Pparg† peroxisome proliferator activated receptor 
gamma
1420715_a_at negative regulation of transcription from RNA 
polymerase II promoter
These genes were identified in profile "BHT-1day_up" (A) and profile "BHT-1day_down" (B) below the p value set for the DAVID analysis (p < 
0.0003)*; see Additional file 2, Table S1 for the complete profile gene lists.
*These genes were identified after bioinformatic analysis filtering first on biological patterns using both Genespring and Spotfire Software followed 
by filtering on GO biological categories using the DAVID Bioinformatics Database. †These genes were upregulated ≥ 2-fold in BALBLsp-d vs. BALB 1 
day following protocol 1 (chronic BHT) (P < 0.05). ‡Significant interaction effects between strain (BALB vs BALBLpsd mice) and treatment (oil, 1 or 3 
days following 4BHT) (p < 0.05). Bolded genes are those genes in common with the gene list identified for Protocol 2 (see Table 2).Molecular Cancer 2009, 8:107 http://www.molecular-cancer.com/content/8/1/107
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thesis, protein targeting, and inflammatory and immune
response (Table 1). Transcripts with the BHT_1day_down
profile have functions related to cell cycle and growth, cell
shape, protein targeting, and transcription (Table 2). The
BHT_1day_up profile also includes genes with inflamma-
tion and immune response functions, as would be
expected based on the BALF inflammation cell analysis
from the same animals (data not shown).
An additional expression profile identified by unsuper-
vised analysis only consists of genes with decreased tran-
script levels 1 day following BHT treatment that recover to
control levels in BALB mice 3 days following BHT, but are
still depressed in BALBLps-d (see Additional file 2, Table S1,
Tab A, column N).
We confirmed the change in transcript level seen in the
microarray analysis using qRTPCR. We used RNA from the
same samples used for microarray analysis and, in the case
of Protocol 2, samples from a repeat study with the same
design. qRTPCR analyses confirmed the changes in
expression seen by microarray analysis in genes listed in
Table 1 (epiregulin (Ereg), tenacin C (Tnc), secreted phos-
phoprotein 1 (Spp1), and peroxisome proliferator acti-
vated receptor gamma (Pparg)), as well as other genes with
profile "BHT-1day_up" (chemokine (C-C motif) ligand
17 (Ccl17), fos-like antigen 1 (Fosl1)) that did not fall
below the p value for DAVID, but were significantly differ-
ent between strains (Figure 2).
Pulmonary inflammation differences between the BALB vs. 
BALBLps-d mice during the progression stage of 
tumorigenesis (Protocol 2, "Progression")
BALBLpsd  mice develop significantly more tumors after
MCA/BHT than wild type BALB mice or than BALBLpsd
mice after MCA/oil treatment [20]. We found mean BALF
total protein content and numbers of macrophages, lym-
phocytes, and epithelial cells were significantly increased
during progression (p < 0.05) in the tumor bearing MCA/
BHT BALBLps-d mice compared to the BALBLps-d MCA/oil
controls (Figure 3A). No increases in inflammatory cell
infiltrates were found in the wildtype BALB mice after
either MCA/oil or MCA/BHT.
Histological staining of the same lungs with anti-F4/80 or
anti-CD3 markers for macrophages or T-lymphocytes,
respectively, confirmed the BALF results (Figure 3B). Anti-
F4/80 and anti-CD3 were found primarily adjacent to but
Table 2: Representative gene expression changes decreased in BALBLsp-d compared to BALB mice.
B.
Gene Symbol* Gene Name Affymetrix Probe ID Major GO Category(ies)
Cell cycle and cell growth
Csf1r colony stimulating factor 1 receptor 1419872_at regulation of progression through cell cycle; 
protein amino acid phosphorylation
Fgf7† fibroblast growth factor 7 1422243_at regulation of progression through cell cycle;; signal 
transduction
Gas6 growth arrest specific 6 1417399_at regulation of cell growth
Htra1 htrA serine peptidase 1 1416749_at regulation of cell growth; proteolysis
Itm2b integral membrane protein 2B 1418000_a_at apoptosis
Cell shape and morphogenesis
Itga8† integrin alpha 8 1427489_at cell adhesion
Nox4† NADPH oxidase 4 1419161_a_at cell morphogenesis; electron transport
Pik3r1† phosphatidylinositol 3-kinase, regulatory subunit, 
polypeptide 1 (p85 alpha)
1425515_at negative regulation of cell-matrix adhesion; protein 
amino acid phosphorylation
Postn periostin, osteoblast specific factor 1423606_at cell adhesion
Protein targeting
Arl6ip1 ADP-ribosylation factor-like 6 interacting 
protein 1
1451131_at cotranslational protein targeting to membrane
Tmod1 tropomodulin 1 1422754_at myofibril assembly; muscle thick filament assembly
Transcription, processing, and chromatin structure
Hp1 bp3 heterochromatin protein 1, binding protein 3 1415751_at nucleosome assembly
Klf15 Kruppel-like factor 15 1448181_at regulation of transcription, DNA-dependent
Rora† RAR-related orphan receptor alpha 1420583_a_at regulation of transcription, DNA-dependent
Slu7 SLU7 splicing factor homolog 1420030_at alternative nuclear mRNA splicing, via spliceosome
* These genes were identified after bioinformatic analysis filtering first on biological patterns using both Genespring and Spotfire Software followed 
by filtering on GO biological categories using the DAVID Bioinformatics Database. †These genes were down-regulated ≥ 2-fold in BALBLsp-d vs. 
BALB 1 day following protocol 1 (chronic BHT) (P < 0.05)Molecular Cancer 2009, 8:107 http://www.molecular-cancer.com/content/8/1/107
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not in the tumor parenchyma in BALBLps-d mice; this peri-
tumoral staining was not seen in BALB mouse tumors.
Adenoma tumor size and morphology were not signifi-
cantly different between the strains (data not shown), sug-
gesting the difference in inflammation is not due to
different stages of tumorigenesis or different tumor mor-
phologies. Few F4/80- or CD3-positive-staining macro-
phages or lymphocytes were found in the MCA/oil lung
sections from either strain (data not shown).
Transcriptome changes between the BALB vs. BALBLps-d 
mice during the progression stage of tumorigenesis 
(Protocol 2, "Progression")
We next assessed gene expression differences in control
(MCA/oil) tissue, MCA/BHT dissected tumor tissue, and
MCA/BHT uninvolved tissue, i.e. tissue remaining after
tumor dissection in the same mice. We identified three
biological profiles: up in tumor tissue relative to MCA
alone or uninvolved tissue in the BALB mice and com-
pared to the tumor tissue in BALBLps-d mice ("up in WT
tumor"); up in tumor tissue compared to MCA alone or
uninvolved tissue, and more so in BALBLps-d than BALB
("up in KO tumor"; Figure 4 and Additional file 6, Figure
S3); and down in tumor compared to MCA alone or unin-
volved tissue, and more so in BALB than in BALBLps-d
("down in WT tumor"). As before, we found that super-
vised and unsupervised analysis methods identified over-
lapping response profiles, which we combined into the
three profiles described (i.e. 6 gene expression patterns, 3
per analysis). All genes in these profiles are listed in Addi-
tional file 2, Table S1, Tab A. We then analyzed GO path-
Confirmation of select genes identified using protocol 1  (chronic BHT) in BALB and BALBLps-d mice Figure 2
Confirmation of select genes identified using proto-
col 1 (chronic BHT) in BALB and BALBLps-d mice. 
These genes were selected using the supervised method of 
microarray analysis in both strains 1 and 3 days following 
BHT. Mean and SEM are presented; n = 3 mice/experimental 
group for all. P values are indicated on the graphs for each 
gene; the lines indicate comparisons between BHT treatment 
and corn oil control vehicle or between BALBLps-d compared 
to BALB mice. * P < 0.05 for 3 day following BHT treatment 
versus corn oil vehicle for Ccl17, and no difference was 
found between BALBLps-d and BALB mice.
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Comparison of inflammatory infiltrates in tumor-bearing  BALB and BALBLps-d mice 27 wks post carcinogen Figure 3
Comparison of inflammatory infiltrates in tumor-
bearing BALB and BALBLps-d mice 27 wks post carcin-
ogen. A. Total BALF macrophages, lymphocytes, epithelial 
cells and protein recovered from BALB and BALBLps-d mice 
after MCA or MCA/BHT treatment. Significant increases in 
inflammation in tumor-bearing mice were found in BALBLps-d 
compared to BALB mice. Mean and SEM are presented; n = 6 
mice/experimental group. P values are indicated on the 
graphs for each phenotype (macrophages, lymphocytes, epi-
thelial cells, and total protein); comparisons are between 
MCA/BHT treatment groups and MCA/oil vehicle or 
between BALB and BALBLps-d mice. B. Immunohistological 
staining in BALB and BALBLps-d mice after 27 wks after MCA/
BHT treatment for macrophages and T-lymphocytes using 
F4/80 and CD3 markers, respectively. Bar indicates 100 μm. 
Slides were counterstained with hematoxylin.
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Table 3: Representative gene expression changes increased in BALBLps-d tumors.
Gene Symbol Gene Name Affymetrix Probe ID Major GO Category(ies)
Angiogenesis
Anpep alanyl aminopeptidase 1421424_a_at angiogenesis; proteolysis
Col18a1† procollagen, type XVIII, alpha 1 1418237_s_at angiogenesis
Nus1 nuclear undecaprenyl pyrophosphate synthase 1 
homolog
1419915_at angiogenesis; multicellular organismal development
Apoptosis and cell death
Bcl2l14 bcl2-like 14 1424814_a_at apoptosis
Cideb† cell death-inducing DNA fragmentation factor, 
alpha subunit-like effector B
1418976_s_at apoptosis; induction of apoptosis
Pglyrp1 peptidoglycan recognition protein 1 1449184_at apoptosis; immune response
Cell cycle and cell growth
Aspm asp-like, microcephaly associated 1422814_at cell cycle; mitosis
Ereg† Epiregulin 1419431_at regulation of progression through cell cycle; 
angiogenesis
Cenpf centromere protein F 1427161_at G2 and M phase of mitotic cell cycle
Mycn v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived
regulation of progression through cell cycle; 
regulation of transcription, DNA-dependent
Immune response
Clcf1 cardiotrophin-like cytokine factor 1 1437270_a_at cell surface receptor linked signal transduction; JAK-
STAT cascade
Flt3l FMS-like tyrosine kinase 3 ligand 1422115_a_at lymphocyte differentiation
H2-oa histocompatibility 2, O region alpha locus 1419297_at immune response; antigen processing and 
presentation
Klrb1b killer cell lectin-like receptor subfamily B 
member 1B
1420421_s_at negative regulation of natural killer cell mediated 
cytotoxicity
Raet1a retinoic acid early transcript 1, alpha 1420603_s_at positive regulation of immune response to tumor 
cell
Inflammatory response and chemotaxis
Ccr1 chemokine (C-C motif) receptor 1 1419610_at inflammatory response; signal transduction
Cxcl4†; Pf4 platelet factor 4; chemokine (C-X-C motif) 
ligand 4
1448995_at chemotaxis; immune response
Cxcl5, Ena-
78
chemokine (C-X-C motif) ligand 5 1419728_at chemotaxis; inflammatory response
Cxcl9†, Mig chemokine (C-X-C motif) ligand 9 1418652_at inflammatory response; immune response
Cxcl11†, Itac chemokine (C-X-C motif) ligand 11 1419697_at chemotaxis; inflammatory response
Kng1 kininogen 1 1416676_at inflammatory response; blood coagulation
Spp1† secreted phosphoprotein 1 1449254_at ossification; anti-apoptosis
Protein synthesis and turnover
Cdkn2a† cyclin-dependent kinase inhibitor 2A 1450140_a_at regulation of cyclin-dependent protein kinase 
activity; cell cycle
Cfi†‡ Complement component factor i 1418724_at proteolysis; immune response
Gzme granzyme E 1421227_at proteolysis; cytolysis
F10 coagulation factor X 1449305_at proteolysis
These genes were identified in the "Up-in-KO_tumor" profile (A) and "Down in WT tumor" profile (B) that are below the p value set for the 
DAVID analysis (p < 0.0001); see Additional file 2, Table S1 for the complete profile gene lists.
*Representative increased genes from the "Up-in-KO_tumor" profile that were higher in the BALBLpsd tumors compared to BALB mice. These 
genes were identified after bioinformatic analysis filtering first on biological patterns using both Genespring and Spotfire Software followed by 
filtering on GO biological categories using the DAVID Bioinformatics Database. †Genes upregulated ≥ 1.5-2-fold in BALBLspd tumors vs. BALB 
tumors based on GeneSpring. ‡Genes with significant interaction effects comparing strain (BALB vs BALBLspd) and treatment (MCA, MCA/BHT 
tumors, MCA/BHT uninvolved tissue) (p < 0.05). Bolded genes are those genes in common with the gene list identified for the 4BHT study (see 
Table 1).Molecular Cancer 2009, 8:107 http://www.molecular-cancer.com/content/8/1/107
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ways for the genes in these three profiles using DAVID
(Additional file 2: Table S1, Tab B, genes within selection
criteria; Tab D are the GO categories for late genes). Tran-
scripts with "up in KO tumor" profiles are associated with
immune response, inflammatory response and chemo-
taxis, apoptosis and cell death, protein synthesis and turn-
over, and cell cycle and cell growth (Table 3). Transcripts
with "down in WT tumor" profiles are primarily associ-
ated with immune response and inflammation (Table 4).
Transcripts with "up in WT tumor" profiles are associated
with angiogenesis, protein synthesis, and immune
responses.
qRTPCR was done to confirm the expression identified by
microarray analysis (Figure 5) on select genes from Table
3 (collagen, type XVIII, alpha 1 (Col18a1), complement
Table 4: Representative gene expression changes decreased in BALB tumors.
Gene Symbol Gene Name Affymetrix Probe ID Major GO Category(ies)
Angiogenesis
F13a1 coagulation factor XIII, A1 subunit 1448929_at tRNA aminoacylation for protein translation; blood 
coagulation
Kdr† kinase insert domain protein receptor 1449379_at angiogenesis; ovarian follicle development
Tbx1† T-box 1 1425779_a_at angiogenesis; blood vessel development
Apoptosis and cell death
Rassf5 ras association (RalGDS/AF-6) domain family 5 1422637_at apoptosis; cell cycle
Unc5c unc-5 homolog C 1449522_at apoptosis; signal transduction
Immune response
Cd3d† CD3 antigen, delta polypeptide 1422828_at protein complex assembly; cell surface receptor 
linked signal transduction
Cd79a CD79A antigen 
(immunoglobulin-associated alpha)
1418830_at immune response; cell surface receptor linked signal 
transduction
Cr2† complement receptor 2 1425289_a_at immune response; complement activation, classical 
pathway
Ltb lymphotoxin B 1419135_at immune response; lymph node development
Ppbp†, Cxcl7 pro-platelet basic protein 1418480_at immune response
Slamf1 signaling lymphocytic activation molecule family 
member 1
1425570_at lymphocyte activation
Tnfrsf13c tumor necrosis factor receptor superfamily, 
member 13c
1419307_at B cell homeostasis; positive regulation of germinal 
center formation
Inflammatory response and chemotaxis
Ccl5† chemokine (C-C motif) ligand 5 1418126_at chemotaxis; inflammatory response
Ccr2 chemokine (C-C motif) receptor 2 1421186_at chemotaxis; inflammatory response
Chst1 carbohydrate (keratan sulfate Gal-6) 
sulfotransferase 1
1449147_at carbohydrate and galactose metabolic process
Enpp2 ectonucleotide pyrophosphatase/
phosphodiesterase 2
1415894_at chemotaxis; metabolic process
S100a8 S100 calcium binding protein A8 1419394_s_at chemotaxis
Protein synthesis and turnover
Cfd complement factor D (adipsin) 1417867_at proteolysis; immune response
Gzma granzyme A 1417898_a_at proteolysis; apoptosis
Transcription, processing, and chromatin structure
Hipk2 homeodomain interacting protein kinase 2 1429566_a_at negative regulation of transcription from RNA 
polymerase II promoter
Myst3 MYST histone acetyltransferase 3 1436315_at nucleosome assembly
SpiB Spi-B transcription factor 1460407_at regulation of transcription, DNA-dependent
These genes were identified in the "Up-in-KO_tumor" profile (A) and "Down in WT tumor" profile (B) that are below the p value set for the 
DAVID analysis (p < 0.0001); see Additional file 2, Table S1 for the complete profile gene lists.
*Representative decreased genes from the "Down in WT tumor" profile for genes BALB tumors compared to BALBLsp-d tumors. These genes were 
identified after bioinformatic analysis filtering first on biological patterns using both Genespring and Spotfire Software followed by filtering on GO 
biological categories using the DAVID Bioinformatics Database. †Genes down-regulated ≥ 50% in BALB tumors compared to BALBLspd tumors 
based on GeneSpring.Molecular Cancer 2009, 8:107 http://www.molecular-cancer.com/content/8/1/107
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component factor i (Cfi), Ereg, kininogen 1 (Kng1), Spp1)
that varied between the tumors in BALB and BALBLps-d
mice, and three additional genes (parathyroid hormone-
like peptide (Pthlh), claudin 2 (Cldn2), arginase 1 (Arg1))
that were highly, significantly upregulated in the BAL-
BLpsd tumors compared to BALB tumors, but did not fall
below the p value set for the DAVID analysis. Two genes
in Table 1 from the early protocol (Ereg and Spp1) were
also identified with Protocol 2 (late, progression stage)
possibly indicating transcripts that are involved in both
promotion and progression of tumorigenesis.
We then compared the summary GO categories for the
genes identified using Protocol 1 (tumor promotion;
early) and Protocol 2 (tumor progression; late). Pie charts
illustrate the number of genes in each of 12 summary cat-
egories with altered transcript levels at early and advanced
stages of carcinogenesis (Figure 6). This figure demon-
strates an increase in the number of genes in cell growth,
shape and protein synthesis and targeting, and transcrip-
tion categories early in the response followed by a switch
to more inflammation and immune responses, as well as
apoptosis, protein synthesis, and cell growth, during the
advanced stages of tumorigenesis.
To better understand the role of the microenvironment in
the uninvolved tissue from tumor-bearing lungs in BALB
and BALBLpsd mice, we then analyzed differential tran-
script expression in uninvolved tissue from tumor bearing
lungs. Additional file 2, Table S1 contains those genes dif-
ferentially expressed in uninvolved tissue between strains
(all have p < 0.05 and two-fold or greater change in
expression). The most dominant GO categories in BAL-
BLps-d  uninvolved tissue were immune response (p  <
0.001) and immune system process (p < 0.005) with those
genes upregulated ≥ 2 fold in BALBLps-d uninvolved tissue
compared to BALB uninvolved tissue (e.g. chemokine (C-
C motif) receptor 1 (Ccr2; p < 0.05) (Additional file 2:
Table S1, Tab A and Tab F). The major categories in BALB
uninvolved tissue were hemopoietic cell lineage (p  <
0.004), immune system process (p < 0.015), leukocyte dif-
ferentiation (p < 0.027) for those genes 50% down-regu-
lated (e.g. chemokine (C-C motif) ligand 5 (Ccl5), CD3
antigen, delta polypeptide (Cd3d)) compared to BALBLps-d
(Additional file 2: Table S1, Tab A and Tab E). The analysis
of uninvolved tissue supports the above transcript analy-
sis in micro-dissected tumors where more immune and
inflammatory transcripts were elevated in BALBLpsd and
decreased in BALB mice.
Discussion
We previously demonstrated that lung carcinogenesis was
enhanced in mice with dysfunctional Tlr4, likely due to
greater chronic inflammation during tumor promotion in
the Tlr4 mutant mice relative to the Tlr4 wild type strain
[20]. In the present study, we found that TLR4 also pro-
tects against the inflammation observed during the
advanced stages of tumorigenesis (see Figure 3) which
supports our previous findings [20]. Using transcriptom-
ics and integrative biology, we have also identified Tlr4-
modulated gene expression pathways that distinguish the
tumor promotion stage (Protocol 1) and the progression
stage (Protocol 2) of tumorigenesis. These novel Tlr4-
mediated pathways and gene signatures provide insight to
the protective effect of TLR4 against lung carcinogenesis
and may provide a means to develop diagnostic tests to
identify individuals at risk for the disease.
We identified many novel genes with increased transcript
levels in Tlr4-mutated mice (BALBLps-d) after BHT. These
include  Ereg, heparin-binding EGF-like growth factor
(Hbegf), high mobility group AT-hook 1 (Hmga1), myelo-
cytomatosis oncogene (Myc), Spp1, and Tnc, and they are
associated with GO categories that are consistent with
Analysis of protocol 2 genes increased in the BALBLps-d  tumors compared to BALB tumors Figure 4
Analysis of protocol 2 genes increased in the BAL-
BLps-d tumors compared to BALB tumors. Supervised 
and unsupervised bioinformatic methods were used for these 
analyses. A. Cluster 4 identified using statistical (Genespring) 
analysis. Each vertical line represents one sample for each 
strain for an n = 2 (Un = uninvolved, MCA = 3-methlycholan-
threne, and for BALBLps-d tumor) with the exception of BALB 
tumor (n = 1), indicated by the small horizontal black line 
above each treatment on the x-axis. B. Profile (Spotfire) anal-
ysis similar to that of cluster 4. Z-score (y-axis) is the inten-
sity in terms of standard deviations (SD) from the mean. The 
z-score is calculated by subtracting the mean and dividing by 
the SD for each probeset. See Additional file 6, Figure S3 for 
supervised and unsupervised analysis depicted as heat maps.
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Confirmation of select genes identified during progression (Protocol 2; MCA/BHT) in the BALB and BALBLps-d mice Figure 5
Confirmation of select genes identified during progression (Protocol 2; MCA/BHT) in the BALB and BALBLps-d 
mice. These genes were selected based on the supervised microarray analysis in both strains 27 wks following MCA/BHT. 
Genes upregulated in the BALBLps-dmice compared to BALB mice. Mean and SEM are presented; n = 4-5 mice/experimental 
group. P values are indicated on the graphs for each gene; comparisons are between MCA/BHT treatment and MCA/oil con-
trols or between BALBLps-d compared to BALB mice.
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early stages of carcinogenesis (cell cycle and growth, ang-
iogenesis, protein synthesis and targeting, and transcrip-
tion). Ereg and Hbegf are epidermal growth factor receptor
(EGFR) ligands that can bind and activate the ERBB family
of receptors [27]. EREG is an intratumoral marker for
advanced NCSLC [28] and is upregulated in cancer cell
lines [29,30]. Spp1  is a chemokine-like protein that
appears to have a role in macrophage infiltration, among
other functions [31], and has been identified as a lung AC
biomarker [32]. Spp1 can also be activated by Kirstein ras
proto-oncogene (K-RAS) in lung neoplasia [33]. Because
Ereg and Spp1 (among others) are elevated at early (during
promotion) and late (during progression) stages, these
genes may play a role in the transition from initiated cell
through promotion (adenomas) to progression (carcino-
mas).
Mutated Tlr4 caused increased inflammation in tumor-
bearing mice (Figure 3). The majority of the transcripts
that were significantly decreased in the uninvolved tissue
in the BALB mice compared to BALBLps-d mice were from
genes involved in inflammation and immune responses,
e.g. Ccl5 and Cd3d (Additional file 2, Table S1). Addition-
ally, transcripts from immune response genes (such as
Ccr2) were increased in the BALBLps-d uninvolved tissue
compared to BALB uninvolved tissue. Thus, these data are
consistent with the increased inflammation observed in
the BALF from BALBLps-d mice (Figure 3). For example,
CCR2 is the receptor for monocyte chemoattractant pro-
tein-1 (MCP-1) that modulates the innate immune
response and recruits monocytes/macrophages to sites of
inflammation [34]. In uninvolved tissue from the BALBLps-
d  mice treated with MCA/BHT, we found a 1.5-fold
increase in MCP-1 protein levels above MCA/oil controls
compared to no increase in the BALB mice (preliminary
ELISA analysis not shown). Because macrophages were
recruited to the lungs but do not infiltrate the tumors [35],
it is not surprising that chemokines specific to these cell
types were upregulated in uninvolved tissue.
Some overlap in biological functions were found based
on our analysis (see Fig 6). For example, GO categories for
cell cycle and growth (Ereg), inflammation (Spp1), and
development (ornithine decarboxylase (Odc1)) contained
genes identified in promotion and progression expression
patterns for BALBLpsd  upregulated genes. Arg1  induces
polyamine synthesis and hence proliferation, through
ODC1 and was also significantly up-regulated in the BAL-
BLps-d tumors (Figure 5; [35]).
Based on the major GO categories identified, we propose
that several key pathways are influenced by TLR4 defi-
ciency during carcinogenesis (Figure 7). Many of the genes
identified during promotion (e.g. Ereg, Hbegf, and Spp1)
can signal through EGFR or are involved in EGFR signal-
ing events which can then lead to cell growth and eventual
tumor development (Figure 7A). Other genes inhibited by
EGFR signaling, such as gap junction protein alpha 1
(Gja1), a mediator for cell-cell communication in lung
epithelial cells that is down-regulated in human and
mouse lung cancer [36,37], were elevated in the BALB
mice (Gja1, confirmed by PCR, data not shown). Thus,
during promotion, the EGFR pathway may drive the pro-
liferative response in the Tlr4 mutant mice while inhibit-
ing cell-cell communication, which provides a growth
advantage for the initiated cells. During progression (Fig-
ure 7B), many inflammation, chemotactic and immune
response genes were elevated in the BALBLps-d mice and
decreased in the BALB mice, likely providing a more
aggressive microenvironment for tumor growth. At the
same time, several proliferative pathways were elevated in
the BALBLps-d  mice (e.g. EGFR), further increasing the
chance of tumor growth and progression. Thus, based on
our analysis of pathways downstream of TLR4 or those
downstream of mice lacking TLR4, it will be important to
Pie chart comparison of the genes involved during early and  late stages of carcinogenesis Figure 6
Pie chart comparison of the genes involved during 
early and late stages of carcinogenesis. Protocol 1 (pro-
motion; Figure 1A-B) and protocol 2 (advanced; Figure 4A-B) 
genes representing the major GO categories for these early 
and more advanced events during tumorigenesis are com-
pared. Pie charts represent the number of genes in each 
group; largest circle contains 19 genes, the smallest 1. Proto-
col 2 colors: Down_BALB_Tumor, navy; Up_BALB_Tumor, 
aqua; Up_BALBLps-d_Tumor, bright green. Protocol 1 colors: 
Down_BALBLps-d_BHT_1dy, maroon; Up_BALBLps-d 
_BHT_1dy, magenta; BHT_1day_BALB_recovery, orange. 
Genes selected in both Protocols are in yellow.
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Proposed pathways for promotion (A) and progression genes (B) influenced by TLR4 Figure 7
Proposed pathways for promotion (A) and progression genes (B) influenced by TLR4. A. Promotion genes prima-
rily signal through or are involved in EGFR signaling which may lead to cell growth and eventual tumor development. Thus, the 
EGFR pathway may drive the proliferative response in mice deficient in Tlr4 and concurrently inhibit communication between 
cells (Gja1), thus providing a growth advantage. References for gene interactions not described in text: Ran, [49]; Myc, [50]; 
Hmag1, [51]; Tnc, [52]; Mina, [53], Timp2 [54]. Symbols: red, genes increased in BALBLps-d mice 1 day Protocol 1; blue, genes 
decreased in BALBLps-d mice 1 day Protocol; green, genes increased in BALB mice 1 day Protocol 1. B. During progression, the 
combination of inflammation observed in BALBLps-d mice in concert with up-regulation of these and other immune response 
genes, the many inflammation and immune response genes that were down regulated in BALB mice, and the additional contri-
bution of cell growth genes (e.g. SPP1; [31], MCP-1; [55], supports a role of TLR4 in protection against lung tumor progression. 
Symbols: red, genes increased in BALBLps-dtumors; blue, genes decreased in BALB tumors; green, genes increased in BALB 
tumors; grey, protein changes in uninvolved tissue from the BALBLps-d mice. *Also decreased in BALB uninvolved tissue; **Also 
increased in BALBLps-d uninvolved tissue. Abbreviations: Ccr2, chemokine (C-C motif) receptor 1; Chst1, carbohydrate sul-
fotransferase 1, Cxcl2, chemokine (C-X-C motif) ligand 2; Enpp2, ectonucleotide phosphodiesterase 2; Il1rn, interleukin 1 
receptor antagonist; S100a8, S100 calcium binding protein A8; Timp2, tissue inhibitor of metalloproteinases; Utrn, utrophin.
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focus future studies on these specific pathways to further
elucidate the mechanisms of TLR4-mediated protection
against BHT-induced inflammation and tumor promo-
tion, as the two phenomena are certainly linked. How-
ever, other genes that were over the set p value for the
DAVID analysis with the progression study (and thus not
found in Tables 3 and 4) but that were identified in the
"up_KO_tumor" profile, provide additional evidence for
similarities between the early and advanced stages of car-
cinogenesis. For example, Pthlh (Figure 5) is located in the
pulmonary adenoma susceptibility 1 (Pas1) gene cluster
near Kras on mouse chromosome 6 [38]. Pthlh  is also
associated with decreased survival in lung AC patients
[39] possibly through EGFR ligand activation [33]. In
addition, PTHLH induces MCP-1 in prostate cancer which
can lead to increased proliferation [40].
Several investigations have characterized gene transcripts
in human and mouse lung AC [25,41-45]. Stearman et al.
[25] compared human and mouse genes responsible for
lung AC; one gene identified was (Spp1) that was
increased in BALBLps-d during both protocols (Tables 1, 2,
3 and 4). However, several other genes in our study were
either significantly upregulated (such as Tyms, thymi-
dylate synthase) or downregulated (such as Aldh1a1, alde-
hyde dehydrogenase 1a1, and Vwf, Von Willebrand
factor) in the tumors from both strains (all ≥ 2-fold or ≥
50%; p < 0.05), similar to the A/J mice used by Stearman
et al. These genes may be more general markers of
advanced stages of tumorigenesis and their identification
in our study supports the comparison between species
and strain. The mouse lung AC model was similar to
human AC in the molecular changes that occurred during
carcinogenesis [25]. In a microarray study using K-ras
over-expressing mice, Ereg was identified as a significantly
upregulated transcript in lung tumors [43], which also
supports our results. Additional human microarray stud-
ies that assessed lung tissue from smokers [44], and tumor
tissue from patients with AC and squamous cell carci-
noma, another NSCLC, identified other unique genes
[41,42,45] such as Cdkn1a, cyclin-dependent kinase
inhibitor 1A (P21), up in BALBLps-d (Table 1). Thus, a
number of the genes identified in the present study were
also identified in human studies and were all associated
with either inflammation or cell growth. However, due to
the specific TLR4 focus in our model, as well as differences
in tumor histology and grade, tumor size, node status, and
margin status, many of the genes we identified were not
found in these human and mouse microarray studies. In
addition, the numbers of the presumptive bronchioalveo-
lar stem cells (BASCs) expressing both a type II cell (pro-
surfactant apoprotein C; SPC) and Clara cell specific
marker (Clara cell 10 kD protein; CC10) may also influ-
ence gene expression in these different models [46].
Conclusion
In summary, based on our transcriptome analysis, the
protective effect of TLR4 in lung carcinogenesis involves
inhibition of multiple pathways, many of which overlap
and likely interact, such as the EGFR and PTHLH path-
ways (Figure 7). EGFR activating mutations in human
NSCLC correlates to positive Gefitinib (EGFR kinase
inhibitor) responsiveness, thus deficiency in TLR4 in
humans may further activate this pathway [47,48]. These
studies have identified a novel panel of genes differen-
tially expressed in mice with sufficient or deficient TLR4
during tumor promotion (such as those genes up-regu-
lated in BALBLps-d: amphiregulin (Areg),  Ereg,  Hbegf,
Hmga1, Myc, myc induced nuclear antigen (Mina), ras-
related nuclear protein (Ran), Spp1, and Tnc; see Figure
7A) and during progression stages of tumorigenesis (such
as genes up-regulated in BALBLps-d tumors: Arg1, chemok-
ine (C-C motif) receptor 1 (Ccr1), platelet factor 4 (Pf4),
chemokine (C-X-C motif) ligand 5 (Cxcl5), Cxcl9, Cxcl11,
Ereg, Kng1, Odc1, Pthlh, and Spp1, see Figure 7B). These
gene panels for early and advanced stages of tumorigene-
sis may be predictive determinants for tumor susceptibil-
ity in those individuals with altered innate immune
systems. The mouse model will allow us to test the signif-
icance of these genes in lung AC using in vivo and in vitro
molecular techniques, such as transgenic or knock-out
mice/cells, as well as siRNA, in order to elucidate addi-
tional pathways to target for future therapies. In addition,
these gene profiles may aid in our understanding of those
individuals occupationally exposed to endotoxin who
appear to have reduced lung cancer risk [15-17].
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